{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:03:28Z","timestamp":1779217408124,"version":"3.51.4"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972638 81972195 82172879"],"award-info":[{"award-number":["81972638 81972195 82172879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2019JJ30038"],"award-info":[{"award-number":["2019JJ30038"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Alectinib, a highly selective inhibitor of ALK, is currently used in the first-line setting of untreated advanced ALK-positive NSCLC and in the second-line setting of crizotinib-resistant ALK-positive NSCLC. Despite promising efficacy and tolerability in the treatment of advanced ALK-positive NSCLC, the activity of alectinib as neoadjuvant therapy in resectable ALK-positive NSCLC remains to be investigated.<\/jats:p><jats:p><jats:bold>Case presentation:<\/jats:bold> Herein, we report a case of a 58-year-old female patient presented to our hospital with hemoptysis for 1\u00a0month. Contrast-enhanced computerized tomography (CT) of the chest showed an approximately 4.2 \u00d7 3.4\u00a0cm mass in the right hilum with localized obstructive pneumonia in the right lower lobe and multiple enlarged lymph nodes in the right hilum and mediastinum. Serum oncological markers results showed elevated levels of CA19-9, CEA, CA125, and CA242. Bronchoscopic biopsy of the mass showed poorly differentiated pulmonary adenocarcinoma and immunohistochemical testing results confirmed ALK positivity. Neoadjuvant alectinib was given at a dosage of 600\u00a0mg twice per day for two cycles (56\u00a0days), achieving a partial response of the disease with 90% shrinkage of the mass at the subsequent whole-body positron emission tomography. Repeat serum oncological markers results showed that only CA125 was elevated, but lower than before therapy. A bilobectomy of the right middle and lower lobes and systemic lymphadectomy under video-assisted thoracoscopic approach was successfully performed 7\u00a0days after the last dose of alectinib. Postoperative pathology showed pathological complete response (pCR). The patient experienced an uneventful postoperative course and continued to receive alectinib and did not report any specific discomfort at her 8-month follow-up. Thoracoabdominal CT at 8\u00a0months postoperatively showed no recurrence and repeated examination of serum oncological markers were negative.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We report a case of resectable ALK-positive NSCLC treated with neoadjuvant aletinib achieving pCR. Our case highlights the feasibility of alectinib as neoadjuvant therapy for the treatment of resectable ALK-positive NSCLC. Undoubtedly, the safety and efficacy of this novel treatment modality needs to be explored in future large clinical trials.<\/jats:p>","DOI":"10.3389\/fphar.2022.816683","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T16:50:21Z","timestamp":1657126221000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1111\/1759-7714.14045","article-title":"Pathological Complete Response to Neoadjuvant Ceritinib of a Crizotinib-Resistant, Stage IIIB Non-small Cell Lung Cancer with ALK Rearrangement: A Case Report","volume":"12","author":"Bing","year":"2021","journal-title":"Thorac. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer Statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"iv116","DOI":"10.1093\/annonc\/mdi920","article-title":"Neoadjuvant Chemotherapy for Stage IIIA-N2 Non-small Cell Lung Cancer","volume":"16","author":"De Marinis","year":"2005","journal-title":"Ann. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-small Cell Lung Cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and Activity of Alectinib against Systemic Disease and Brain Metastases in Patients with Crizotinib-Resistant ALK-Rearranged Non-small-cell Lung Cancer (AF-002JG): Results from the Dose-Finding Portion of a Phase 1\/2 Study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus Crizotinib in Patients with ALK-Positive Non-small-cell Lung Cancer (J-ALEX): an Open-Label, Randomised Phase 3 Trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic Lymphoma Kinase Inhibition in Non-small-cell Lung Cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.cllc.2021.02.014","article-title":"Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Trial","volume":"22","author":"Leonetti","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-10-3879","article-title":"Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors","volume":"71","author":"Lovly","year":"2011","journal-title":"Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4065\/83.5.584","article-title":"Non-small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative Chemotherapy for Non-small-cell Lung Cancer: a Systematic Review and Meta-Analysis of Individual Participant Data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-small-cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.21037\/tlcr-20-780","article-title":"Neoadjuvant Treatment of Stage IIIA-N2 in EGFR-Mutant\/ALK-Rearranged Non-small Cell Lung Cancer","volume":"10","author":"Reyes","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","article-title":"Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population","volume":"15","author":"Rodig","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","article-title":"Targeting Anaplastic Lymphoma Kinase in Lung Cancer","volume":"17","author":"Shaw","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the Transforming EML4-ALK Fusion Gene in Non-small-cell Lung Cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-08-1018","article-title":"Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts","volume":"14","author":"Takeuchi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jtho.2018.10.161","article-title":"Neoadjuvant Crizotinib in Resectable Locally Advanced Non-small Cell Lung Cancer with ALK Rearrangement","volume":"14","author":"Zhang","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.jtho.2019.12.133","article-title":"Feasibility and Safety of Neoadjuvant Alectinib in a Patient with ALK-Positive Locally Advanced NSCLC","volume":"15","author":"Zhang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","article-title":"Gefitinib as Neoadjuvant Therapy for Resectable Stage II-IIIA Non-small Cell Lung Cancer: A Phase II Study","volume":"161","author":"Zhang","year":"2021","journal-title":"J. Thorac. Cardiovasc Surg."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.816683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T16:50:24Z","timestamp":1657126224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.816683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":23,"alternative-id":["10.3389\/fphar.2022.816683"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.816683","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"article-number":"816683"}}